Shares of Humacyte declined sharply in morning trading, sliding 21.6% to $1.05 after the company priced an underwritten public offering for $50 million at that same level. The price represented a meaningful discount versus where the stock had been trading before the offering was announced.
The deal contemplates issuance of approximately 47.6 million shares of common stock and is expected to close on or about Friday, June 12. Underwriters have been granted a 30-day option to buy up to an additional 7.1 million shares at the identical $1.05 price.
The dilutive effect of the equity sale is the principal driver of the stock's intraday weakness. That pressure was only partially offset by Humacyte's simultaneous disclosure of top-line interim results from its V012 Phase 3 trial in female dialysis patients, presented at the Society of Vascular Surgery's Vascular Annual Meeting in Boston.
According to the company, the trial achieved its primary endpoint. Patients treated with Humacyte's acellular tissue engineered vessel - ATEV - averaged 220 catheter-free days, compared with 129 catheter-free days for patients receiving a standard arteriovenous fistula. The company's chief medical officer characterized the outcome as "a very meaningful improvement for female patients who often have fewer good choices."
Humacyte said it will apply the net proceeds from the offering to support commercialization of its FDA-approved Symvess product and to finance a planned supplemental Biologics License Application filing for hemodialysis access in the second half of 2026.
Market context did not provide a lift for Humacyte's shares: the broader U.S. equity benchmarks were positive on the session, with the S&P 500 up 0.6%, the Dow Jones gaining 0.7%, and the NASDAQ rising 0.7%. That divergence underscores that the decline in Humacyte's share price was driven by company-specific factors.
The stock had already traded lower in after-hours activity the prior evening when the offering was announced before pricing was finalized, indicating investors anticipated dilution irrespective of the favorable clinical news.
Combined with the company's recent financials - including a first-quarter net loss of $17.6 million - and references to a going-concern backdrop, the mechanics of a deeply discounted equity raise proved sufficient to outweigh the positive Phase 3 data in investors' assessments. The shares moved to align with the offering price during the session as market participants reacted to the prospective increase in share count.
What happened
- Humacyte priced a $50 million underwritten public offering at $1.05 per share, the same price at which the stock traded after the move.
- The offering comprises about 47.6 million common shares, with a 30-day underwriter option for up to 7.1 million additional shares at the same price.
- Top-line interim V012 Phase 3 results in female dialysis patients met the trial's primary endpoint, showing an average of 220 catheter-free days for ATEV recipients versus 129 for arteriovenous fistula recipients.
Why it matters
- The financing introduces significant dilution at a deeply discounted price, which pressured the stock despite positive clinical data and an approved product.
- Proceeds are earmarked to commercialize Symvess and to support a supplemental BLA filing for hemodialysis access in the second half of 2026.
- Company-specific financial considerations, including a Q1 net loss of $17.6 million and a referenced going-concern backdrop, were factors in investor assessment.